Stocks Health care YDES
NASDAQ · Health careYD Bio Ltd (YDES)
YD Bio Ltd reported revenue of $596.8K in fiscal 2025, up 16.9% from a year earlier. It posted a net loss of $8.3M. In fiscal 2025 capital spending exceeded operating cash flow by $8M. At December 31, 2025 it held $6M in cash against $6.8K of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on April 30, 2026.
Key facts about YD Bio Ltd
- Net worth
- YD Bio Ltd has a market value (market cap) of $475.3M at the latest share price, and shareholders' equity of -$2.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $596.8K (+16.9% year on year), with a net loss of $8.3M.
- Cash flow
- In fiscal 2025 operations used $6.6M of cash.
- Latest report
- The latest periodic report (annual report (foreign issuer), 20-F) was filed with the SEC on April 30, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What YD Bio Ltd does
YD Bio Ltd is registered with the SEC under industry code SIC 8071 (Services-Medical Laboratories). Its shares trade on NASDAQ under the ticker YDES.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $596.8K | -$8.3M | -$0.12 | -$8M |
| 2025 | $510.4K | -$1.4M | -$0.02 | -$1.3M |
| 2023 | $350.1K | $13.6K | $0.00 | -$55.9K |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where YDES ranks in Health care
Latest SEC filings
What YD Bio Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 11, 2026
- May 26, 2026Form POS AM filing POS AM
- May 1, 2026
- April 30, 2026Annual report (foreign issuer) 20-F · period to December 31, 2025Revenue rose 17% to $596.8K versus the prior year; diluted EPS -$0.12 versus -$0.02.
- February 26, 2026
- February 17, 2026Passive stake changed SCHEDULE 13G/A
- January 30, 2026
- January 21, 2026
- January 16, 2026
Insider trades
What the people running YD Bio Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $128.5K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Chang KochiDirector | Exercised options | 3,135 | - |
| September 30, 2026 | Lu Shao-TaDirector | Exercised options | 3,135 | - |
| September 14, 2026 | Shen Ethan PhDCEO, Director | Bought | 12,700 | $48.9K |
| September 9, 2026 | Shen Ethan PhDCEO, Director | Bought | 3,100 | $12.2K |
| September 4, 2026 | Shen Ethan PhDCEO, Director | Bought | 18,378 | $67.4K |
| June 30, 2026 | Chang KochiDirector | Exercised options | 5,749 | - |
| June 30, 2026 | Lu Shao-TaDirector | Exercised options | 5,749 | - |
| March 31, 2026 | Chang KochiDirector | Exercised options | 2,081 | - |
Who owns YDES
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Ethan Shen13G, passive with 1 related filers | 77.06% | February 17, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 11,280,261 shares in total, about $75.7M at the last price.
| Holder | Shares |
|---|---|
| Shen Ethan PhDCEO, Director | 11,258,331 |
| Lu Shao-TaDirector | 10,965 |
| Chang KochiDirector | 10,965 |
Questions about YDES
What does YD Bio Ltd do?
YD Bio Ltd is a company in the Health care sector, listed on NASDAQ as YDES. Its shares trade on NASDAQ under the ticker YDES.
What is YD Bio Ltd's net worth?
YD Bio Ltd has a market value (market cap) of $475.3M at the latest share price, and shareholders' equity of -$2.9M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is YD Bio Ltd profitable?
No. In fiscal 2025 it reported a net loss of $8.3M on revenue of $596.8K.
How much revenue does YD Bio Ltd make?
In fiscal 2025 YD Bio Ltd reported revenue of $596.8K. That is 16.9% more than a year earlier.
When did YD Bio Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on April 30, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the insider trade from October 6, 2026.
Similar companies
Compare YDES with
Follow YDES
Get an email when YD Bio Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values YD Bio Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.